SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision
📖

FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear Palsy

active
wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-fnp223-prosper-phas
Related Entities
clinical-trials-fnp223-prosper-phase2-psp
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
35
Outgoing
76
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Linked Artifacts (111)
mentions🧪Microglial Purinergic Reprogramming100%
mentions🧪Aquaporin-4 Polarization Rescue100%
mentions🧪Netrin-1 Gradient Restoration100%
mentions🧪Glial Glycocalyx Remodeling Therapy100%
mentions🧪Ephrin-B2/EphB4 Axis Manipulation100%
mentions🧪Sphingolipid Metabolism Reprogramming100%
mentions🧪Complement C1q Subtype Switching100%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
mentions🔬PSP and CBD both involve 4R-tau but produce distinct neuropa60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
see_also📖Aging vs Neurodegeneration: Mechanistic Comparison Matrix60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
see_also📖Alzheimer Indonesia60%
see_also📖Apoptosis in Neurodegeneration60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
see_also📖Packard Center for ALS Research60%
see_also📖DUSP10 Gene60%
see_also📖Genes60%
mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
see_also📖Dementia Australia60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
see_also📖cdkn2a60%
see_also📖diseases-amyotrophic-lateral-sclerosis60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
see_also📖Frontotemporal Dementia (FTD)60%
see_also📖Autophagy Enhancement Drug Screening for Neurodegeneration60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%
related🧫Metabolic Pathway-Targeted Therapy in ALS54%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%
related🧫Progranulin Replacement Therapy for FTD — Vector Development54%
related🧫N-of-1 Clinical Trial Design for CBS/PSP54%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp54%
related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa54%
related🧫TDP-43 PET Ligand Development for FTD and ALS54%
related🧪Noradrenergic-Tau Propagation Blockade50%
related🧪Serine/Arginine-Rich Protein Kinase Modulation50%
related🧪Optogenetic Control of Mitochondrial Transfer Networks50%
mentions🧪Phase-Separated Organelle Targeting50%
related🧪Lysosomal Membrane Repair Enhancement50%
mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%
related🧪HSP90-Tau Disaggregation Complex Enhancement50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🔬TDP-43 undergoes liquid-liquid phase separation that becomes50%
mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%
related🧪Mitochondrial-Lysosomal Contact Site Engineering50%
mentions🧪Competitive APOE4 Domain Stabilization Peptides50%
mentions🧫PSP and CBS Biomarker Validation Study50%
mentions🧫4R-Tau Targeting Therapies for PSP and CBS50%
mentions🧫Tau Pathology Initiation Zone Identification50%
mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%
mentions🧪Stress Granule Phase Separation Modulators50%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri50%
mentions🧪APOE Isoform Expression Across Glial Subtypes50%
related🔬What are the mechanisms underlying microglia-astrocyte cross50%
related🧪Lysosomal Enzyme Trafficking Correction50%
mentions🧫Brainstem Circuit Modulation for PSP50%
mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre50%
related🔬What are the mechanisms underlying microglia-astrocyte cross50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🧪Pharmacological Enhancement of APOE4 Glycosylation50%
related🧪Lysosomal Calcium Channel Modulation Therapy50%
related🧪Synaptic Vesicle Tau Capture Inhibition50%
mentions🧫Tau Spreading Network Mapping via Spatial Transcriptomics in50%
related🧪Phase-Separated Organelle Targeting40%
mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%
related🧪Stress Granule Phase Separation Modulators40%
mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes40%

💬 Discussion

SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub